Turning next to TACSTD2 (TROP2), the target of a clinically approved ADC for triple-negative breast and bladder cancers (with additional clinical trials underway in lung adenocarcinoma and prostate cancer), we noted TROP2 expression in most CRPC–adenocarcinoma clusters but with no correlation with AR expression (Fig. 4D). This evidence concerns the gene TACSTD2 and prostate carcinoma.